Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin

Neth J Med. 2008 May;66(5):204-6.

Abstract

Neuromyopathy is a rare side effect of chronic colchicine therapy, most often occurring in patients with chronic renal failure. Drugs interacting with colchicine metabolism through CYP(3)A(4) and P-glycoprotein can accelerate accumulation and toxicity. We describe a case of an interaction between clarithromycin and colchicine resulting in acute neuromyopathy, and we conclude that combined use of macrolides and colchicine should be avoided.

Publication types

  • Case Reports

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Aged
  • Anti-Bacterial Agents / adverse effects*
  • Anticholesteremic Agents / adverse effects
  • Clarithromycin / adverse effects*
  • Colchicine / adverse effects*
  • Cytochrome P-450 CYP3A
  • Drug Interactions
  • Humans
  • Kidney Failure, Chronic / physiopathology*
  • Male
  • Neuromuscular Diseases / chemically induced*
  • Risk Factors
  • Simvastatin / adverse effects
  • Tubulin Modulators / adverse effects*

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Anti-Bacterial Agents
  • Anticholesteremic Agents
  • Tubulin Modulators
  • Simvastatin
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Clarithromycin
  • Colchicine